Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
about
Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use
P2860
Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Pharmacokinetic/pharmacodynami ...... b for the treatment of asthma.
@en
Pharmacokinetic/pharmacodynami ...... b for the treatment of asthma.
@nl
type
label
Pharmacokinetic/pharmacodynami ...... b for the treatment of asthma.
@en
Pharmacokinetic/pharmacodynami ...... b for the treatment of asthma.
@nl
prefLabel
Pharmacokinetic/pharmacodynami ...... b for the treatment of asthma.
@en
Pharmacokinetic/pharmacodynami ...... b for the treatment of asthma.
@nl
P2860
P1476
Pharmacokinetic/pharmacodynami ...... b for the treatment of asthma.
@en
P2093
Barbara Rinaldi
Maria Gabriella Matera
P2860
P304
P356
10.1080/17425255.2017.1359253
P407
P577
2017-07-24T00:00:00Z